TheStreet lowered shares of GlaxoSmithKline PLC (NYSE:GSK) from a b rating to a c+ rating in a research report released on Wednesday morning.

A number of other equities analysts have also recently issued reports on the company. BNP Paribas lowered their target price on GlaxoSmithKline PLC to $37.00 in a report on Thursday, April 6th. Berenberg Bank upgraded GlaxoSmithKline PLC from a hold rating to a buy rating in a report on Friday, May 26th. Zacks Investment Research upgraded GlaxoSmithKline PLC from a hold rating to a buy rating and set a $47.00 target price for the company in a report on Tuesday, July 18th. ValuEngine cut GlaxoSmithKline PLC from a buy rating to a hold rating in a report on Friday, June 2nd. Finally, Citigroup Inc. cut GlaxoSmithKline PLC from a buy rating to a neutral rating in a report on Wednesday, July 5th. Two equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and ten have given a buy rating to the company. The stock currently has an average rating of Hold and an average target price of $46.00.

Shares of GlaxoSmithKline PLC (NYSE GSK) opened at 40.93 on Wednesday. The company’s 50-day moving average price is $42.84 and its 200-day moving average price is $41.78. GlaxoSmithKline PLC has a 52-week low of $37.20 and a 52-week high of $45.58. The firm has a market cap of $100.03 billion, a PE ratio of 40.36 and a beta of 1.04.

GlaxoSmithKline PLC (NYSE:GSK) last released its quarterly earnings data on Wednesday, July 26th. The pharmaceutical company reported $0.70 EPS for the quarter, beating the Zacks’ consensus estimate of $0.68 by $0.02. GlaxoSmithKline PLC had a net margin of 6.48% and a return on equity of 114.93%. The business had revenue of $9.36 billion during the quarter, compared to analysts’ expectations of $9.52 billion. Equities analysts expect that GlaxoSmithKline PLC will post $2.84 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This report was first posted by Watch List News and is owned by of Watch List News. If you are accessing this report on another website, it was stolen and reposted in violation of U.S. and international trademark & copyright legislation. The legal version of this report can be accessed at https://www.watchlistnews.com/glaxosmithkline-plc-gsk-cut-to-c-at-thestreet/1462213.html.

The company also recently announced a quarterly dividend, which will be paid on Thursday, October 12th. Investors of record on Friday, August 11th will be paid a $0.491 dividend. This is an increase from GlaxoSmithKline PLC’s previous quarterly dividend of $0.46. This represents a $1.96 annualized dividend and a yield of 4.80%. The ex-dividend date of this dividend is Wednesday, August 9th. GlaxoSmithKline PLC’s dividend payout ratio (DPR) is 194.00%.

A number of large investors have recently modified their holdings of the stock. Bronfman E.L. Rothschild L.P. increased its stake in shares of GlaxoSmithKline PLC by 45.4% in the first quarter. Bronfman E.L. Rothschild L.P. now owns 2,410 shares of the pharmaceutical company’s stock valued at $102,000 after buying an additional 753 shares during the period. Nelson Van Denburg & Campbell Wealth Management Group LLC increased its stake in shares of GlaxoSmithKline PLC by 1,747.4% in the first quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 2,494 shares of the pharmaceutical company’s stock valued at $105,000 after buying an additional 2,359 shares during the period. Proficio Capital Partners LLC increased its stake in shares of GlaxoSmithKline PLC by 233.0% in the first quarter. Proficio Capital Partners LLC now owns 2,844 shares of the pharmaceutical company’s stock valued at $122,000 after buying an additional 1,990 shares during the period. Heritage Trust Co purchased a new stake in shares of GlaxoSmithKline PLC during the first quarter valued at about $123,000. Finally, Westwood Holdings Group Inc. increased its stake in shares of GlaxoSmithKline PLC by 15.7% in the first quarter. Westwood Holdings Group Inc. now owns 2,950 shares of the pharmaceutical company’s stock valued at $124,000 after buying an additional 400 shares during the period. Institutional investors and hedge funds own 8.98% of the company’s stock.

GlaxoSmithKline PLC Company Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Analyst Recommendations for GlaxoSmithKline PLC (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.